<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00159926</url>
  </required_header>
  <id_info>
    <org_study_id>959583153</org_study_id>
    <secondary_id>961501172</secondary_id>
    <secondary_id>DHF: 03-2-3-35-22109</secondary_id>
    <secondary_id>CHC: 20/fo03</secondary_id>
    <nct_id>NCT00159926</nct_id>
  </id_info>
  <brief_title>Cleansing of Suction Blood in Cardiac Surgery for Reduced Inflammatory Response</brief_title>
  <official_title>Does Cleansing of Suction Blood During Cardiac Surgery With Heart and Lung Machine Reduce the Postoperative Inflammatory Response ?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Danish Heart Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Copenhagen Hospital Corporation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac surgery using heart and lung machine produces an inflammatory reaction in the body.&#xD;
      This leads in few percent of cases to heart, lung, and kidney disturbances that potentially&#xD;
      causes death. White blood cells in contact with the heart and lung machine and external&#xD;
      surfaces release mediators partly responsible for this. Blood collected by the suction and&#xD;
      the blood remaining in the heart and lung machine after its use, can be cleaned by a cell&#xD;
      saver before reinfusion, and this might reduce the inflammatory response.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction&#xD;
&#xD;
      Cardiopulmonary bypass (CPB) during cardiac surgery induces in all patients a systemic&#xD;
      inflammatory response syndrome (SIRS) that is more pronounced than for other surgical&#xD;
      procedures. Depending on the severity of this, myocardial dysfunction, respiratory failure,&#xD;
      renal and neurological dysfunction, coagulation disturbances and impaired liver function&#xD;
      might follow. In worst cases this leads to acute respiratory distress syndrome, disseminated&#xD;
      intravascular coagulation, multi organ failure, shock and death. The cause is besides the&#xD;
      surgical trauma, the passage of the blood through the extra corporal circulation (ECC) and&#xD;
      its pumps and oxygenator, hemodilution, hypothermia, heparin and protamine administration,&#xD;
      ischemia and reperfusion, and endotoxemia (LPS) as a cause of intestinal ischemia. The ECC is&#xD;
      the main cause of immunological activation and leads in severe cases to the so-called&#xD;
      post-perfusion syndrome. This is characterised by increased capillary permeability and&#xD;
      intercellular fluid, peripheral vasoconstriction, fever, myocardial edema, diffuse cerebral&#xD;
      edema and diffuse hemorrhagic diathesis. This syndrome is considered to be a more severe form&#xD;
      of SIRS. Even though most patients have no sequelae after CPB, all patients must be&#xD;
      considered to be influenced, in varying degree, by SIRS. High levels of pro-inflammatory&#xD;
      cytokines (interleukin (IL)-6, IL-8, IL-1a, IL-1b, tumor necrosis factor (TNF) alfa), have&#xD;
      generally been associated with adverse events after CPB. Of importance is also LPS from&#xD;
      gram-negative intestinal bacteria, translocating to the systemic circulation during ischemia.&#xD;
&#xD;
      Hypothesis&#xD;
&#xD;
      Cleansing of suction blood and the remaining blood in the ECC after termination of CPB,&#xD;
      reduces the load of inflammatory cells and mediators in the patients' circulation. This&#xD;
      potentially diminishes SIRS with a reduction in postoperative organ dysfunction and&#xD;
      morbidity.&#xD;
&#xD;
      Aim&#xD;
&#xD;
      To cleanse suction blood and the remaining blood in the ECC after termination of CPB by means&#xD;
      of a cell saver and monitor the influence on inflammatory mediators and the potential&#xD;
      clinical benefits.&#xD;
&#xD;
      Outcome measures&#xD;
&#xD;
      Primary: Concentrations of IL-1B, IL-6, IL-8, IL-10, IL-12p70, TNFa, TNF-R1, TNF-R2, PCT and&#xD;
      LPS in patient blood: 6, 24 and 72 hours after termination of CPB.&#xD;
&#xD;
      Secondary: Bleeding, need for allogenic blood transfusions and blood products and clinical&#xD;
      effect focusing on known complications to cardiac surgery and CPB.&#xD;
&#xD;
      Design&#xD;
&#xD;
      Prospective randomised clinical trial including 40 patients planned for on-pump coronary&#xD;
      artery bypass grafting (CABG). n=20 in the trial group (use of cell saver) and n=20 in the&#xD;
      control group (no cell saver). No patients receive postoperative autotransfusion of drain&#xD;
      blood.&#xD;
&#xD;
      Sample size&#xD;
&#xD;
      Estimation based on comparable studies.&#xD;
&#xD;
      Anaesthesia and surgery&#xD;
&#xD;
      In accordance with current guidelines of the clinic, this includes prophylactic antibiotics&#xD;
      (cefuroxime and gentamycin). Cell saver: Medtronic Autolog.&#xD;
&#xD;
      Patient exclusion during the trial&#xD;
&#xD;
      Patients are excluded in cases of autotransfusion of blood not cleansed by the cell saver,&#xD;
      for instance in cases of major blood loss.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    For financial and logistical reasons&#xD;
  </why_stopped>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentrations of IL-1B, IL-6, IL-8, IL-10, IL-12p70, TNFa, TNF-R1, TNF-R2, PCT and LPS in patient blood.</measure>
    <time_frame>6, 24 and 72 hours after termination of CPB.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>Intra- and postoperatively</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for allogenic blood transfusions and blood products</measure>
    <time_frame>Within submission</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical effect focusing on known complications to cardiac surgery and CPB</measure>
    <time_frame>Within submission</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Systemic Inflammatory Response Syndrome</condition>
  <condition>Coronary Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>With cell saver</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Without cell saver</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cell saver</intervention_name>
    <description>Cell saver intraoperatively for coronary artery bypass grafting using cardiopulmonary bypass</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>No cell saver</intervention_name>
    <description>Conventional suction for coronary artery bypass grafting using cardiopulmonary bypass</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Oral and written informed consent.&#xD;
&#xD;
          -  No limits regarding age or ejection fraction.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Off-pump coronary artery bypass grafting&#xD;
&#xD;
          -  Redo CABG&#xD;
&#xD;
          -  Current infection&#xD;
&#xD;
          -  Antibiotic treatment&#xD;
&#xD;
          -  S-creatinin &gt; 200 micromol/L&#xD;
&#xD;
          -  Antiinflammatory / immuno-modulating treatment: Steroids, immunosuppressive or&#xD;
             -stimulating agents (NSAIDs and ASA allowed)&#xD;
&#xD;
          -  Liver disease&#xD;
&#xD;
          -  Immune disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sune Damgaard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Cardiothoracic Surgery, Rigshospitalet, Copenhagen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel A Steinbr√ºchel, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Dept. of Cardiothoracic Surgery, Rigshospitalet, Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiothoracic Surgery, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <last_update_submitted>January 4, 2008</last_update_submitted>
  <last_update_submitted_qc>January 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2008</last_update_posted>
  <keyword>systemic inflammatory response syndrome</keyword>
  <keyword>coronary artery bypass grafting</keyword>
  <keyword>cell saver</keyword>
  <keyword>interleukins</keyword>
  <keyword>tumor necrosis factor alfa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

